Dr Tares Krassanairawiwong, secretary-general of the Thai FDA shares the recent reforms carried out in the hope of facilitating greater patient access to both domestic and internationally-produced treatments. Dr Krassanairawiwong also highlights the institution’s current priorities, including medical cannabis, positioning Thailand as a clinical trials hub, and further developing the country’s biopharmaceutical industry.
To keep pace with what is a disruptive world, the Thai FDA has had to update and evaluate its strategic plan
